Updated just now · Live
Stock analysis, price data, and AI-powered insights for Olema Pharmaceuticals Inc (OLMA).
Olema Pharmaceuticals Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for OLMA.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). OLMA Stock Intelligence Report. [stoxpulse.com/stocks/olma]
Disclaimer: The information on this page about Olema Pharmaceuticals Inc (OLMA) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Olema Pharmaceuticals Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Olema Pharmaceuticals Reveals Preclinical Data For...
3d ago
Olema Oncology Announces Preclinical Data for Pala...
3d ago
StoxPulse AI results for OLMA: Pulse Score 50/100. Primary sentiment trends from 2 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$1.45B
P/E Ratio
—
EPS
$-0.49
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Olema Pharmaceuticals Reveals Preclinical Data For Palazestrant and OP-3136 At The 2026 AACR Annual Meeting; Palazestrant's Mechanism Of Action Confirmed; Full Recruitment Of Corepressor Protein NCoR1 Enables Complete Antagonism Of The Estrogen Receptor; Palazestrant Is Currently Being Evaluated In Two Phase 3 Clinical Trials; OP-3136 Is Enrolling Patients In The Ongoing Phase 1 Study
Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting